Michael Fischbach

Monogram Biosciences, Inc. develops and commercializes diagnostic products for the treatment of human immunodeficiency virus (HIV) infection, hepatitis C virus (HCV) infection, and other viral illnesses, as well as cancer and other diseases. It offers HIV tests, including genotypic, phenotypic, tropism, and combined phenotype and genotype assays, suppression management and viral load testing, HCV assays and oncology tests. The company was founded in 1995 and is headquartered in South San Francisco, CA.

Achaogen, Inc. engages in developing and commercializing innovative antibacterial agents for multi-drug resistant gram-negative infections. The firm is also involved in the development of C-Scape, an orally administered antibiotic to address a serious unmet need for an effective oral treatment for patients with complicated urinary tract infections, including pyelonephritis caused by extended spectrum beta-lactamases producing Enterobacteriaceae. The company was founded by Nathaniel Eames David, Floyd E. Romesberg, and Peter G. Schultz in June 2002 and is headquartered in South San Francisco, CA.

The Column Group LLC is a venture capital firm founded in 2005 by Peter Svennilson. The firm is headquartered in San Francisco.

Part of University of California, California Institute For Quantitative Biosciences is a biotech company that offers internships to UC students through its state-funded Qwest internship program. The company is based in San Francisco, CA and was founded in 2000. The program places students with Bakar Labs tenant companies for work experience, and four of its first cohort have already received full-time job offers from their hosts. The company conducts proof-of-concept experiments in a mouse model of ALS and offers mentoring programs to early-stage companies.

Zymergen, Inc. engages in the design, development, and commercialization of bio-based products. Its products include electronic films, repellent products, and agriculture products such as traditional synthetic nitrogen fertilizers and traditional chemical-based crop protection products. The company was founded by Zachariah Serber, Jed Dean and Joshua J. Hoffman in 2013 and is headquartered in Emeryville, CA.

Federation Bio, Inc. uses microbiome therapeutics to address medical needs. The company was founded by Racquel N. Bracken, Michael Fischbach and Dylan Dodd and is headquartered in South San Francisco, CA.

Kelonia Therapeutics, Inc. is a company based in Cambridge, MA that is pioneering a new wave of genetic medicines using its in vivo gene placement system (iGPS™). The company's simple and elegant cutting-edge in vivo gene delivery technology uses a few potent lentiviral vector-like particles to precisely and efficiently deliver in vivo genetic cargo to the desired target tissue, and only that tissue, every time. Initially focused on developing transformational in vivo CAR T therapies for hematologic cancers, Kelonia Therapeutics is building a pipeline of genetic medicines for a range of diseases, with the bold goal of making genetic medicines accessible to every patient in need, when and where they need them. The company was founded by Michael Fischbach, Michael Birnbaum.